AbbVie Ventures is focused on early-stage opportunities in oncology, immunology, neuroscience, eye care, and aesthetics.
Active portfolio
opens in a new windowAccent Therapeutics is leading the translation of RNA-modifying protein(RMP)biology into promising new precision therapies for cancer.
opens in a new windowExpanding the druggable proteome to drug intrinsically disordered proteins.
opens in a new windowAM–Pharma is developing disease modifying Alkaline Phosphatase therapeutics.
ApoGen Biotechnologies is developing a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.
opens in a new windowAquinnah Pharmaceuticals is developing small molecule therapeutics targeting persistent stress granules for the treatment of neurodegenerative disease.
opens in a new windowArtios Pharma is developing cancer treatments that target DNA Damage Response pathways to selectively kill cancer cells.
opens in a new windowCapsida Therapeutics is creating a new class of targeted gene therapies for both CNS and non-CNS disorders.
opens in a new windowCaraway Therapeutics is developing novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy.
opens in a new windowCarisma Therapeutics is developing Chimeric Antigen Receptor-expressing macrophages to target and destroy solid tumors.
DG Medicines is employing a novel drug discovery platform to identify therapeutics for targeted protein degradation.
opens in a new windowDisc Medicine is developing therapies addressing ineffective red blood cell production in hematologic diseases.
EndLyz Therapeutics is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias.
opens in a new windowEnthera is developing first-in-class therapeutics for severe autoimmune disorders.
opens in a new windowE-Scape Bio is developing therapeutics against genetic targets for neurodegenerative disease.
Faze Medicines is pioneering therapeutics based on the groundbreaking new science of biomolecular condensates.
FireCyte is an emerging biotechnology company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye.
opens in a new windowJnana Therapeutics is building the first drug discovery platform dedicated to the solute carrier family of transporters.
opens in a new windowKojin Therapeutics is developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology.
opens in a new windowMagnolia Neurosciences is developing potent and highly selective neuroprotective therapies.
opens in a new windowNitrase Therapeutics is developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases.
opens in a new windowPACT is developing personalized adoptive cell therapies based on neoantigen-targeted T cells against cancer.
opens in a new windowPalleon Pharmaceuticals is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
opens in a new windowQuanta Therapeutics is pioneering allosteric modulation to control RAS signaling for inhibition of the full scope of RAS-driven cancer types.
opens in a new windowRibometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human disease.
opens in a new windowRibon Therapeutics is discovering first-in-class small molecule inhibitors to block cancer cells' ability to survive under stress.
opens in a new windowStemson Therapeutics is developing a novel treatment for hair loss, using iPS cells to grow new Dermal Papilla and generate hair follicles de novo.
opens in a new windowTrishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.
Stealth NewCo
Chemoproteomics Stealth NewCo is developing activity-dependent protein ligation technology for quantitative in-cell profiling.
Stealth NewCo
Protein Degradation Stealth NewCo is developing small molecule enhancers of the proteasome.
Stealth NewCo
Cell Surfaceome Stealth NewCo is developing novel mass spectrometry methods to decode the cell surface.
The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?
The link below will take you out of the AbbVie family of websites. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. The Internet site that you have requested may not be optimized to your screen size. Do you wish to leave this site?